Mesothelin gene expression and promoter methylation/hypomethylation in gynecological tumors

European Journal of Gynaecological Oncology

Volumn 31, Issue 1, 2010, Pages 63-71

  Obulhasim, G ^a,b   Fujii, Hiroaki ^a   Matsumoto, T ^a   Yasen, M ^a,b   Abe, M ^a   Matsuoka, S ^a   Ohtsuji, N ^a   Hino, O ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Gynecological tumors; Hypomethylation; Mesothelin; Overexpression; Promoter methylation

Indexed keywords

MESOTHELIN; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; CPG ISLAND; CYSTADENOCARCINOMA; DNA METHYLATION; ENDOMETRIUM CARCINOMA; FEMALE; FEMALE GENITAL TRACT TUMOR; GENE EXPRESSION; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; SEX CORD TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; CPG ISLANDS; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 77349110458     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Chang K., Pastan I.: "Molecular cloning and expression of a cDNA encoding a protein detected by the K1 antibody from an ovarian carcinoma (OVCAR-3) cell line". Int. J. Cancer, 1994, 57, 90.
2. Hassan R., Bera T., Pastan I.: "Mesothelin: a new target for immunotherapy". Clin. Cancer Res., 2004, 10 (12 Pt 1), 3937.
3. Chang K., Pastan I., Willingham M.C.: "Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesomelium". Int. J. Cancer, 1992, 50, 373.
4. Cao D., Ji H., Ronnett B.M. "Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary". Int. J. Gynecol. Pathol., 2005, 24, 67.
5. Chang K., Pastan I., Willingham M.C. "Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas". Int. J. Cancer, 1992, 51, 548.
6. Dainty L.A., Risinger J.I., Morrison C., Chandramouli G.V., Bidus M.A., Zahn C., et al.: "Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma". Gynecol. Oncol., 2007, 105, 563.
7. Frierson H.F., Jr., Moskaluk C.A., Powell S.M., Zhang H., Cerilli L.A., Stoler M.H., et al.: "Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas". Hum. Pathol., 2003, 34, 605.
8. Hassan R., Laszik Z.G., Lerner M., Raffeid M., Postier R., Bracken D.: "Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis". Am. J. Clin. Pathol., 2005, 124, 838.
9. Hassan R., Remaley A.T., Sampson M.L., Zhang J., Cox D.D., Pingpank J. et al.: "Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer". Clin. Cancer Res., 2006, 12, 447.
10. Ho M., Bera T.K., Willingham M.C., Onda M., Hassan R., FitzGerald D., et al. "Mesothelin expression in human lung cancer". Clin. Cancer Res., 2007, 13, 1571.
11. Ho M., Hassan R., Zhang J., Wang Q.C., Onda M., Bera T. et al.: "Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients". Clin. Cancer Res., 2005, 11, 3814.
12. Hough C.D., Sherman-Baust C.A., Pizer E.S., Montz F.J., Im D.D., Rosenshein N.B. et al.: "Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer". Cancer Res., 2000, 60, 6281.
13. Ordonez N.G. "Application of mesothelin immunostaining in tumor diagnosis". Am. J. Surg. Pathol., 2003, 27, 1418.
14. Robinson B.W., Creaney J., Lake R., Nowak A., Musk A.W., de Klerk N. et al.: "Mesothelin-family proteins and diagnosis of mesothelioma". Lancet, 2003, 362, 1612.
15. Shiomi K., Hagiwara Y., Sonoue K., Segawa T., Miyashita K., Maeda M. et al.: "Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma". Clin. Cancer Res., 2008, 14, 1431.
16. Robinson B.W., Creaney J., Lake R., Nowak A., Musk A.W., de Klerk N. et al.: "Soluble mesothelin-related protein-a blood test for mesothelioma". Lung Cancer, 2005, 49 (suppl. 1.), S109.
17. Sato N., Maitra A., Fukushima N., van Heek N.T., Matsubayashi H., Iacobuzio-Donahue C.A. et al.: "Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma". Cancer Res., 2003, 63, 4158.
18. Hucl T., Brody J.R., Gallmeier E., Iacobuzio-Donahue C.A., Farrance I.K., Kern S.E.: "High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif". Cancer Res., 2007, 67, 9055.
19. Kuppuswamy M.N., Hoffmann J.W., Kasper C.K., Spitzer S.G., Groce S.L., Bajaj S.P.: "Single nucleotide primer extension to detect genetic diseases: experimental application to hemophilia B (factor IX) and cystic fibrosis genes". Proc. Natl. Acad. Sci. U S A, 1991, 88, 1143.
20. Gonzalgo M.L., Jones P.A.: "Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE)". Nucleic Acids Res., 1997, 25, 2529.
21. Gonzalgo M.L., Liang G.: "Methylation-sensitive single-nucleotide primer extension (Ms-SNuPE) for quantitative measurement of DNA methylation". Nat. Protoc., 2007, 2, 1931.
22. Chang K., Pai L.H., Batra J.K., Pastan I., Willingham M.C.: "Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium". Cancer Res., 1992, 52, 181.
23. Drapkin R., Crum C.P., Hecht J.L.: "Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia". Hum. Pathol., 2004, 35, 1014.
24. Hassan R., Kreitman R.J., Pastan I., Willingham M.C.: "Localization of mesothelin in epithelial ovarian cancer". Appl. Immunohistochem. Mol. Morphol., 2005, 13, 243.
25. Hellstrom I., Friedman E., Verch T., Yang Y., Korach J., Jaffar J. et al.: "Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients". Cancer Epidemiol. Biomarkers Prev., 2008, 17, 1520.
26. Yen M.J., Hsu C.Y., Mao T.L., Wu T.C., Roden R., Wang T.L. et al.: "Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma". Clin. Cancer Res., 2006, 12(3 Pt 1), 827.
27. Rump A., Morikawa Y., Tanaka M., Minami S., Umesaki N., Takeuchi M. et al.: "Binding of ovarian cancer antigen CA 125/MUC16 to mesothelin mediates cell adhesion". J. Biol Chem., 2004, 279, 9190.
28. Chang K., Pastan I. "Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers". Proc. Natl. Acad. Sci. USA, 1996, 93, 136.
29. Hellstrom I., Raycraft J., Kanan S., Sardesai N.Y., Verch T., Yang Y. et al.: "Mesothelin variant 1 is released from tumor cells as a diagnostic marker". Cancer Epidemiol. Biomarkers Prev., 2006, 15, 1014.
30. Muminova Z.E., Strong T.V., Shaw D.R.: "Characterization of human mesothelin transcripts in ovarian and pancreatic cancer". BMC Cancer, 2004, 4, 19.
31. Scholler N., Fu N., Yang Y., Ye Z., Goodman G.E., Hellstrom K.E. et al.: "Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma". Proc. Natl. Acad. Sci. USA, 1999, 96, 11531.
32. Urwin D., Lake R.A. "Structure of the Mesothelin/MPF gene and characterization of its promoter". Mol. Cell Biol. Res. Commun., 2000, 3, 26.
33. Hassan R., Ebel W., Routhier E.L., Patel R., Kline J.B., Zhang J. et al.: "Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin". Cancer Immun., 2007, 7, 20.